Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience

Chiara Tani, Elena Elefante, Viola Signorini, Dina Zucchi, Valentina Lorenzoni, Linda Carli, Chiara Stagnaro, Francesco Ferro, Marta Mosca, Chiara Tani, Elena Elefante, Viola Signorini, Dina Zucchi, Valentina Lorenzoni, Linda Carli, Chiara Stagnaro, Francesco Ferro, Marta Mosca

Abstract

Objectives: To evaluate the proportion of patients who have successfully withdrawn glucocorticoids (GCs) in a longitudinal cohort of patients with systemic lupus erythematosus (SLE) over a period of 6 years; to evaluate patient characteristics during GC withdrawal in relation to existing definitions of remission and Lupus Low Disease Activity State (LLDAS); and to evaluate the occurrence of flares after GC withdrawal.

Methods: Patients who attempted GC withdrawal were identified for the cohort, and the following information was assessed during withdrawal attempts: date of last disease flare, disease activity and damage and ongoing treatment. Information regarding the occurrence of disease flares after GC withdrawal was also recorded for patients who successfully stopped treatment.Definitions of remission were applied to GC withdrawal in line with European consensus criteria (Definitions of remission in SLE [DORIS]) and LLDAS in line with the Asian Pacific Lupus Consortium definition.

Results: 148 patients were involved in the study; GC withdrawal was attempted in 91 patients (61.5%) with 77 patients (84.6%) successfully stopping GCs. At the beginning of the GC reduction, the majority of patients were in complete or clinical remission (48.9% and 39.6%, respectively). Disease activity was significantly lower in patients who successfully stopped GCs, and the proportion of patients in complete remission was higher (54.2%) with respect to patients who failed in their attempt. Among patients who stopped GCs, 18 flares were recorded after a median of 1 year. The time period since the last flare was shorter in patients who experienced flares with respect to patients who did not flare (mean 0.93 years vs 6.0, p<0.001).

Conclusions: GC withdrawal is an achievable goal in SLE and may be attempted after a long-term remission or LLDAS to protect the patient from disease flares.

Keywords: glucocorticoids; low disease activity state; remission.

Conflict of interest statement

Competing interests: None declared.

References

    1. Mosca M, Tani C, Carli L, et al. . Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011;29(5 Suppl 68):S126–9.
    1. Little J, Parker B, Lunt M, et al. . Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort. Rheumatology 2018;57:677–87. 10.1093/rheumatology/kex444
    1. Gladman DD, Urowitz MB, Rahman P, et al. . Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955–9.
    1. Zonana-Nacach A, Barr SG, Magder LS, et al. . Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801–8. 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>;2-O
    1. Keeling SO, Bissonauth A, Bernatsky S, et al. . Practice variations in the diagnosis, monitoring, and treatment of systemic lupus erythematosus in Canada. J Rheumatol 2018;45:1440–7. 10.3899/jrheum.171307
    1. van Staa TP, Leufkens HGM, Cooper C, et al. . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–87. 10.1007/s001980200108
    1. Dixon WG, Abrahamowicz M, Beauchamp M-E, et al. . Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128–33. 10.1136/annrheumdis-2011-200702
    1. Raúl Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, et al. . Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998;29:259–62.
    1. Bruce IN. 'Not only… but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005;44:1492–502. 10.1093/rheumatology/kei142
    1. Bhangle SD, Kramer N, Rosenstein ED. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int 2013;33:1923–32. 10.1007/s00296-013-2750-z
    1. Alderaan K, Sekicki V, Magder LS, et al. . Risk factors for cataracts in systemic lupus erythematosus (SLE). Rheumatol Int 2015;35:701–8. 10.1007/s00296-014-3129-5
    1. van Vollenhoven RF, Mosca M, Bertsias G, et al. . Treat-to-target in systemic lupus erythematosus: recommendations from an international Task Force. Ann Rheum Dis 2014;73:958–67. 10.1136/annrheumdis-2013-205139
    1. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. . Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res 2018;70:582–91. 10.1002/acr.23322
    1. Drenkard C, Villa AR, García-Padilla C, et al. . Remission of systematic lupus erythematosus. Medicine 1996;75:88–98. 10.1097/00005792-199603000-00005
    1. Steiman AJ, Urowitz MB, Ibañez D, et al. . Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808–16. 10.3899/jrheum.131137
    1. Moroni G, Longhi S, Giglio E, et al. . What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol 2013;31:S75–81.
    1. Moroni G, Gallelli B, Quaglini S, et al. . Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006;21:1541–8. 10.1093/ndt/gfk073
    1. Moroni G, Gatto M, Raffiotta F, et al. . Can we withdraw immunosuppressants in patients with lupus nephritis in remission? an expert debate. Autoimmun Rev 2018;17:11–18. 10.1016/j.autrev.2017.11.003
    1. Mosca M, Tani C, Aringer M. Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin Exp Rheumatol 2013;31(4 Suppl 78):S71–4.
    1. Bertsias GK, Tektonidou M, Amoura Z, et al. . Joint European League against rheumatism and European renal Association–European dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–82. 10.1136/annrheumdis-2012-201940
    1. Ngamjanyaporn P, McCarthy EM, Sergeant JC, et al. . Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. Lupus Sci Med 2017;4:e000173 10.1136/lupus-2016-000173
    1. van Vollenhoven R, Voskuyl A, Bertsias G, et al. . A framework for remission in SLE: consensus findings from a large international Task Force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554–61. 10.1136/annrheumdis-2016-209519
    1. Franklyn K, Lau CS, Navarra SV, et al. . Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016;75:1615–21. 10.1136/annrheumdis-2015-207726
    1. Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol 2018;70:1790–5. 10.1002/art.40571
    1. Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, et al. . Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology 2017;56:121–8. 10.1093/rheumatology/kew377
    1. Zen M, Iaccarino L, Gatto M, et al. . Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018;77:104–10. 10.1136/annrheumdis-2017-211613
    1. Zen M, Iaccarino L, Gatto M, et al. . The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis 2017;76:562–5. 10.1136/annrheumdis-2016-210154
    1. Tselios K, Gladman DD, Touma Z, et al. . Clinical remission and low disease activity outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res 2018. 10.1002/acr.23720
    1. Mok CC, Ho LY, Tse SM, et al. . Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 2017;76:1420–5. 10.1136/annrheumdis-2016-210382
    1. Golder V, Kandane-Rathnayake R, Hoi AY-B, et al. . Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther 2017;19 10.1186/s13075-017-1256-6
    1. Zen M, Iaccarino L, Gatto M, et al. . Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015;74:2117–22. 10.1136/annrheumdis-2015-207347
    1. Urowitz MB, Feletar M, Bruce IN, et al. . Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005;32:1467–72.
    1. Formiga F, Moga I, Pac M, et al. . High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology 1999;38:724–7. 10.1093/rheumatology/38.8.724
    1. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. . The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine 2004;83:1–17. 10.1097/01.md.0000104742.42401.e2
    1. Zahr ZA, Fang H, Magder LS, et al. . Predictors of corticosteroid tapering in SLE patients: the Hopkins lupus cohort. Lupus 2013;22:697–701. 10.1177/0961203313490434
    1. Ponticelli C, Moroni G, Banfi G. Discontinuation of therapy in diffuse proliferative lupus nephritis. Am J Med 1988;85 10.1016/S0002-9343(88)80366-8

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅